The transcription factor MEF2D directly binds to the ACSL3 promoter region to enhance its transcription, as confirmed by ChIP and luciferase reporter assays (Li et al., 2024). Clinical data reveal a significant positive correlation between MEF2D and ACSL3 expression in HCC, with high levels of both predicting poor patient outcomes (Li et al., 2024). Here, MEF2D is linked to hepatocellular carcinoma.